Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.38 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 2/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | ACVR2A | P27037 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19425826 | 0.84 | LOX (0.46) | LOXLOXL2CCR9CCR1CCR5 | |
| SCHEMBL30947592 | 0.84 | LOX (0.46) | LOXLOXL2CCR1CCR5CCR8 | |
| SCHEMBL14768850 | 0.84 | LOX (0.46) | LOXLOXL2CCR1CCR5CCR8 | |
| SCHEMBL16450612 | 0.82 | NUDT1 (0.50) | LOXLOXL2FGFR2GAKRIPK2 | |
| SCHEMBL15483278 | 0.82 | LOX (0.49) | LOXLOXL2CCR1CCR5CCR8 | |
| SCHEMBL11325805 | 0.82 | LOX (0.47) | LOXLOXL2CCR9CCR1CCR5 | |
| SCHEMBL31121348 | 0.82 | NOS3 (0.52) | LOXLOXL2GAKRIPK2COQ8A | |
| SCHEMBL16230689 | 0.82 | KIF11 (0.35) | LOXLOXL2FGFR2GAKRIPK2 | |
| SCHEMBL20852857 | 0.82 | KIF11 (0.35) | LOXLOXL2FGFR2GAKRIPK2 | |
| SCHEMBL677234 | 0.82 | NOS3 (0.52) | LOXLOXL2GAKRIPK2COQ8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912685-B2 | Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure | FUDAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11912685-B2 | Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure | FUDAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | FORESEE PHARMACEUTICALS USA, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | LOX 2303/4885LOXL2 1841/4885FGFR2 1306/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | LOX 2486/4885LOXL2 892/4885FGFR2 2102/4885 |
| US-20240018131-A1 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | MMP12, MMP1, MMP11 | LOX 175/4885LOXL2 218/4885FGFR2 2655/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | LOX 2012/4885LOXL2 4093/4885FGFR2 4533/4885 |
| US-11912685-B2 | Biphenyl diaryl pyrimidine derivative with aromatic heterocyclic structure | DPYD, TYMP, DHODH | LOX 4572/4885LOXL2 4204/4885FGFR2 653/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | LOX 665/4885LOXL2 341/4885FGFR2 722/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | LOX 2779/4885LOXL2 1089/4885FGFR2 622/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | LOX 2634/4885LOXL2 1728/4885FGFR2 493/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LOX 952/4885LOXL2 321/4885FGFR2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.